1. AB0484 An Integrated Pharmacokinetic and Pharmacodynamic Approach to Guide Dose Selection of Namilumab, an Anti-GM-CSF Monoclonal Antibody, for Phase II Rheumatoid Arthritis Studies. (9th June 2015) Authors: Wagner, T.; Thienel, U.; Vieser, E.; Souberbielle, B.; Lahu, G. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 1059 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anti‐GM‐CSF therapy in psoriasis. (1st June 2019) Authors: Papp, K.A.; Gooderham, M.; Jenkins, R.; Vender, R.; Szepietowski, J.C.; Wagner, T.; Hunt, B.; Souberbielle, B. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: e234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Anti‐GM‐CSF therapy in psoriasis. (3rd June 2019) Authors: Papp, K.A.; Gooderham, M.; Jenkins, R.; Vender, R.; Szepietowski, J.C.; Wagner, T.; Hunt, B.; Souberbielle, B. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: e234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody. (2nd November 2018) Authors: Papp, K.A.; Gooderham, M.; Jenkins, R.; Vender, R.; Szepietowski, J.C.; Wagner, T.; Hunt, B.; Souberbielle, B. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: 1352 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody. (1st June 2019) Authors: Papp, K.A.; Gooderham, M.; Jenkins, R.; Vender, R.; Szepietowski, J.C.; Wagner, T.; Hunt, B.; Souberbielle, B. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: 1352 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody3. (2nd November 2018) Authors: Papp, K.A.; Gooderham, M.; Jenkins, R.; Vender, R.; Szepietowski, J.C.; Wagner, T.; Hunt, B.; Souberbielle, B. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: 1352 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAT0210 First-in-Patient Study of Namilumab, an Anti-GM-CSF Monoclonal Antibody, in Active Rheumatoid Arthritis: Results of the Priora Phase IB Study. (9th June 2015) Authors: Huizinga, T.W.J.; Batalov, A.; Yablanski, K.; Stoilov, R.; Lloyd, E.; Wagner, T.; Saurigny, D.; Souberbielle, B.; Esfandiari, E. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 银屑病抗‐GM‐CSF 治疗. (1st June 2019) Authors: Papp, K.A.; Gooderham, M.; Jenkins, R.; Vender, R.; Szepietowski, J.C.; Wagner, T.; Hunt, B.; Souberbielle, B. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: e251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 银屑病抗‐GM‐CSF 治疗. (3rd June 2019) Authors: Papp, K.A.; Gooderham, M.; Jenkins, R.; Vender, R.; Szepietowski, J.C.; Wagner, T.; Hunt, B.; Souberbielle, B. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: e251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗